Compare WASH & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WASH | PLRX |
|---|---|---|
| Founded | 1800 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 682.2M | 74.9M |
| IPO Year | 1994 | 2020 |
| Metric | WASH | PLRX |
|---|---|---|
| Price | $31.54 | $1.19 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 4 |
| Target Price | ★ $30.25 | $2.67 |
| AVG Volume (30 Days) | 206.5K | ★ 479.9K |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.22% | N/A |
| EPS Growth | ★ 266.26 | 29.97 |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $229,048,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.19 | N/A |
| P/E Ratio | $46.82 | ★ N/A |
| Revenue Growth | ★ 127.57 | N/A |
| 52 Week Low | $25.23 | $1.09 |
| 52 Week High | $37.08 | $1.95 |
| Indicator | WASH | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.46 | 41.56 |
| Support Level | $31.51 | $1.16 |
| Resistance Level | $32.49 | $1.37 |
| Average True Range (ATR) | 0.81 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 47.19 | 35.71 |
Washington Trust Bancorp Inc through its subsidiaries offers banking and financial services to individuals and businesses. It offers a full range of financial services, including commercial banking, mortgage banking, personal banking, and wealth management and trust services, through its offices located in Rhode Island, Connecticut, and Massachusetts. It operates in two segments. The Commercial Banking segment includes lending activities, commercial loans, residential real estate loan deposit activities, and others. The Wealth Management Services segment consists of investment management, financial planning, personal trust, and estate services including services as trustee, personal representative, custodian and guardian, and settlement of decedents' estates.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.